Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02227108 · ClinicalTrials.gov registry record · Phase 2
Study in Pediatrics With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma
A Phase 2 study, sponsored by MedImmune.
- Terminated
- Registry status
- Phase 2
- Development phase
- 37
- Enrollment target
NCT02227108 is a Phase 2 study that was terminated before completion, run by MedImmune. The registered enrollment target is 37 participants.
The verdict
NCT02227108, a Phase 2 study, was terminated before completion, sponsored by MedImmune.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 37 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the efficacy of moxetumomab pasudotox in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) or B-cell lymphoblastic lymphoma.
Interventions
- DRUG Moxetumomab Pasudotox
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2014-08 |
| Est. Completion | 2015-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02227108
The ClinicalTrials.gov registry entry for NCT02227108 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Moxetumomab Pasudotox is the first listed.
NCT02227108 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02227108 about?
NCT02227108 is a clinical study titled "Study in Pediatrics With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma". The primary objective of this study is to evaluate the efficacy of moxetumomab pasudotox in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) or B-cell lymphoblastic lymphoma.
What is the current status of trial NCT02227108?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2014-08. Estimated completion is 2015-11.
What interventions are being tested in trial NCT02227108?
The interventions under investigation include: Moxetumomab Pasudotox (DRUG).
Who is sponsoring clinical trial NCT02227108?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.